A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill

The world of post-approval research is going to get more public, more crowded, and more dangerous to pharma. Post-marketing surveillance, transparent clinical trial results and mandated post-approval studies mean the traditional world of marketing-oriented Phase IV is about to change dramatically.

Cole Werble

The Food & Drug Administration Amendments Act is famously the "drug safety law"—a once-in-forty-years overhaul of FDA authority to bring...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet